LNSR Stock Analysis: Buy, Sell, or Hold?
LNSR - LENSAR, Inc. Common Stock
$6.40
0.56 (9.59%)
▲
5d:
+4.23%
30d:
+11.5%
90d:
+7.2%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When LNSR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: LNSR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: LNSR is currently trading at $6.40, which is considered extended relative to its 30-day fair value range of $5.62 to $6.04. From a valuation perspective, the stock is trading at a discount (Forward PE: -9.0) compared to its historical average (14.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LNSR is in a strong downtrend. The price is approaching resistance at $6.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.50 (+32.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LNSR is in a strong downtrend. The price is approaching resistance at $6.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.50 (+32.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.62 -
$6.04
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- BEARISH: Price extended above range (+6.0% above its trading range)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.6%)
- BULLISH: Trading 32.8% below Wall St target ($8.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$5.62 -
$6.04
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$6.11
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.01
Wall Street Target
$8.50
(+32.8%)
Revenue Growth (YoY)
-5.2%
Profit Margin
50.9%
PE vs Historical
-9.0 vs 14.6
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNSR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
